ストックスクリーナーアプリを入手
230.83
0.14%
-0.32
前日終値:
$231.15
開ける：
$233.6
24時間の取引高:
891.71K
Relative Volume:
1.41
時価総額：
$15.14B
収益：
$1.01B
当期純損益:
$581.90M
株価収益率:
26.01
EPS:
8.8733
ネットキャッシュフロー:
$50.57M
1週間 パフォーマンス:
+7.06%
1か月 パフォーマンス:
-2.87%
6か月 パフォーマンス:
+15.53%
1年 パフォーマンス:
+35.22%
1日の値動き範囲:
$230.23
$237.00
1週間の範囲:
$216.50
$237.00
52週間の値動き範囲:
$160.86
$250.74
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
230.83 | 15.14B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-17 | 開始されました | Raymond James | Strong Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-07 | 開始されました | UBS | Buy |
| 2024-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-06-25 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 開始されました | Stifel | Buy |
| 2023-12-20 | 開始されました | Jefferies | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Neutral |
| 2023-04-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-04-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-08-30 | 再開されました | Berenberg | Buy |
| 2022-03-28 | 再開されました | Wedbush | Outperform |
| 2022-03-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 開始されました | Cowen | Market Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-30 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 再開されました | Stifel | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2019-03-25 | 開始されました | Evercore ISI | Outperform |
| 2019-01-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-01-24 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 開始されました | Stifel | Buy |
| 2018-04-02 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-05-11 | 開始されました | JP Morgan | Overweight |
| 2017-03-09 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 開始されました | Credit Suisse | Outperform |
| 2016-09-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Ascendis Pharma A S (ASND) 最新ニュース
Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ascendis Pharma A/S (ASND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ascendis Pharma A/S (ASND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale - Stock Titan
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $288 - Moomoo
Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says - marketscreener.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com UK
Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com - Investing.com Nigeria
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 - Moomoo
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism - TipRanks
Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits - Stock Titan
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 36.97% Potential Upside - DirectorsTalk Interviews
Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Ascendis Pharma completes Phase 3 PaTHway Trial - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
(ASND) Risk Channels and Responsive Allocation - Stock Traders Daily
Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years - Quiver Quantitative
Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D - Stock Titan
Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock. - Pluang
Why Is Ascendis Pharma Stock Gaining Friday?Ascendis Pharma (NASDAQ:ASND) - Benzinga
Ascendis boasts of long-term Yorvipath data for hypoparathyroidism - MSN
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism - TipRanks
Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND) - Stock Titan
Ascendis reports 5-year data for hypoparathyroidism drug - Investing.com UK
Ascendis reports 5-year data for hypoparathyroidism drug By Investing.com - Investing.com Australia
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years - Moomoo
5-year trial: drug frees most hypoparathyroidism patients from supplements - Stock Titan
Ascendis Pharma Named Among Top Profitable Growth Stocks: Market Recognition BuildsMid-Term Outlook - newsline.com
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share By Investing.com - Investing.com South Africa
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan - TipRanks
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share - Investing.com
[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC FilingForm 6-K - Stock Titan
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Yahoo Finance
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case By Investing.com - Investing.com Australia
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case - Investing.com
10 Most Profitable Growth Stocks to Buy - Insider Monkey
Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026 - Quiver Quantitative
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewswire Inc.
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness - simplywall.st
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness - Yahoo Finance
Why Ascendis Pharma Stock Is Sinking Today - TipRanks
Ascendis Pharma A/S (ASND) Stock Analysis: Unlocking a 40% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Capital International Ltd. CA Sells 4,811 Shares of Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma A/S Stock 12‑Month Price Target Raised to $295.6, Implies 40% Upside - TradingView
TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND - MarketBeat
The Option Play Of The Week (NASDAQ:ASND) - Seeking Alpha
Westfield Capital Management Co. LP Cuts Stake in Ascendis Pharma A/S $ASND - MarketBeat
ASND Technical Analysis | Trend, Signals & Chart Patterns | ASCENDIS PHARMA A/S (NASDAQ:ASND) - ChartMill
Ascendis Pharma reports trial data on achondroplasia treatment - Investing.com
Ascendis Pharma A S (ASND) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):